Stockreport

Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE

Rogers Corporation  (ROG) 
Last rogers corporation earnings: 4/30 04:05 pm Check Earnings Report
US:NYSE Investor Relations: investors.rogers.com
PDF The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FR?), which is over-expressed in most ovarian cancers.The test identifies ovaria [Read more]